Category Archives: Guangdong

Guangdong Drug Exchange Center Publishes First September 2026 Batch of Newly Listed Bargaining‑Price Disinfection Products – Batch YJHCGW39‑20260901‑XD Joins Negotiated Procurement Scope for Hospitals Province‑Wide

Listing Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Platform	Guangdong Third‑Party Drug Electronic Trading Platform – Medical Consumables Trading System
Action	Publication of newly listed bargaining‑price (议价挂网) disinfection products – first batch, September 2026
Batch	YJHCGW39‑20260901‑XD
Publication Date	17 September 2026
Product Scope	Disinfection products (消毒产品) declared by enterprises before 10 September 2026, price‑confirmed and listing‑applied via the automatic confirmation workflow; details in the attached product information table
Transaction Rule	Medical institutions procure by bargaining at prices not exceeding the listed price

Listing Process & Conditions

Automatic Confirmation Workflow: Covered products were declared through the system’s “Price Management – Consumables Bargaining‑Price Listing Addition (Automatic Confirmation Items)” module, where enterprises confirmed price information and submitted listing applications before the 10 September 2026 cut‑off.
Publicity‑Period Gate: Only products that received no objections during the publicity period are published in this batch; enterprises are directed to download the attached detailed product list themselves.
Deferred Listings: Products with information re‑verification pending or with registration certificates not yet fully effective will be listed only after verification concludes or product status becomes fully effective.
Policy Basis: The provincial platform’s announcement on implementing medical consumables listing procurement, the Center’s notice on optimizing routine drug and consumables listing work, and the notice activating the automatic viewing‑and‑confirmation process for bargaining‑price listed consumables price information.

Sector Background

Bargaining‑Price Listing (议价挂网): A procurement channel where the listed price serves as a ceiling and hospitals negotiate final prices with suppliers — distinct from fixed‑price centralized procurement, commonly used for competitively supplied consumables and disinfection products.
Disinfection Products Category: Managed separately from drugs and medical devices under China’s disinfection product regulations, these products (disinfectants, antiseptics, sanitizing agents for medical use) access hospital channels via provincial platforms once listed.
Automation Trend: The automatic price‑confirmation workflow streamlines what was previously manual review — part of Guangdong’s broader digitization of consumables market access with rolling monthly batches.

Market Impact & Outlook

Immediate Hospital Access: Products in this batch become procurable across Guangdong’s medical institutions right away, converting listing into commercial opportunity for successful applicants.
Price Ceiling Discipline: The “no higher than listed price” bargaining rule anchors hospital negotiations at the confirmed ceiling, reinforcing downward price pressure in the disinfection products segment.
Pipeline Watch: Enterprises whose products were held back for re‑verification or pending certificate effectiveness should expect supplementary listings in subsequent batches once conditions are met.
Rolling Cadence: The first‑batch numbering (YJHCGW39‑20260901‑XD) reflects a systematic publication schedule — suppliers not in this batch should pre‑position CA credentials, price confirmations and registration documentation ahead of the next monthly cut‑off.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, deferred publication and procurement uptake of bargaining‑price disinfection products in Guangdong. Actual listing status depends on information re‑verification, registration certificate effectiveness and platform processing, and transaction volumes and prices may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100575340429578240

Guangdong Drug Exchange Center Opens Linkage Price Confirmation Window for Listed Drugs – Batch 20260917 Targets Above‑Benchmark VBP Winners and “Four‑Same” Products, With Delisting and Disqualification Risks for Non‑Compliance

Notice Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Action	Linkage price viewing & confirmation for selected listed drugs
Batch	20260917
Product Scope	① VBP winners (incl. limited‑volume winners) whose provincial winning price exceeds other provinces’; ② same‑enterprise winners under price‑differential/comparison rules; ③ “Four‑Same” drugs listed above the national lowest listing price (as of 16 Sep 2026; details in system)
Confirmation Window	Immediate – 20 Sep 2026, 17:00
Platform	Guangdong Drug & Medical Consumables Procurement Subsystem (CA certificate login)
Policy Basis	National drug price governance requirements

Confirmation Paths & Consequences

Viewing Path (VBP winners above other provinces’ prices): Log in with CA certificate → “Drug Centralized Procurement Management – Drug Price Management – Drug Price Publication – Provincial VBP Winning Product Linkage Price Information Viewing (Batch 20260917).”
Confirmation Path (price‑differential winners & “Four‑Same” drugs): Log in with CA certificate → “Drug Price Confirmation – Provincial VBP Winning Products and ‘Four‑Same’ Drug Linkage Price Confirmation (Batch 20260917).”
Appeal Mechanism: Enterprises disputing prices must upload appeal materials stamped with the company seal on every page via the designated appeal attachment path within the window; late objections or missing evidence will in principle not be accepted.
VBP Winners Above Other Provinces: No objection, or appeal rejected → winning price adjusted downward via linkage automatically.
Price‑Differential Winners: Confirm within deadline → linkage adjustment applies; refuse confirmation with appeal rejected, or miss the deadline → winning qualification cancelled per procurement documents.
“Four‑Same” Listed Drugs: Confirm within deadline → unified price adjustment across the province’s three platforms; refuse with appeal rejected, or miss the deadline → listing revoked, with relisting only via a fresh application through the standard listing process.
Ongoing Self‑Check Duty: Enterprises must monitor prices in other provinces and submit price adjustment applications through the subsystem within 30 days of any new lower winning or listing price taking effect elsewhere.

Sector Background

Linkage Price Mechanism: Cross‑province price linkage forces listed and VBP‑winning prices toward the national lowest benchmark, a core pillar of China’s drug price governance that compresses inter‑provincial price gaps.
“Four‑Same” Targeting: Identical generic name, brand, dosage form and specification — the tightest comparability standard, closing arbitrage where the same product holds different prices across platforms.
Three‑Platform Unification: Confirmed “Four‑Same” adjustments apply uniformly across Guangdong’s three procurement platforms, eliminating within‑province price fragmentation.
Contact Channels: Online customer service via the Guangdong Drug Exchange Center website; hotlines 020‑87709875 / 020‑38036197 (weekdays 8:30–12:00, 14:00–17:30).

Market Impact & Outlook

Immediate Revenue Risk: For affected products, linkage adjustment means direct price cuts in Guangdong, one of China’s largest pharmaceutical markets — material for enterprises with concentrated provincial exposure.
Compliance Deadline Pressure: The four‑day window (closing 20 Sep, 17:00) makes timely CA‑certificate login and price confirmation operationally critical; missed deadlines trigger disqualification or delisting without further recourse.
National Price Discipline: The 30‑day self‑reporting duty institutionalizes continuous downward price surveillance — enterprises should embed cross‑province price monitoring into routine market‑access operations.
Strategic Considerations: Companies facing steep linkage cuts must weigh confirmation against withdrawal economics per product, factoring in relisting costs and the risk of setting new national price precedents.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding linkage price adjustments, appeals outcomes and potential disqualification or delisting of listed drugs in Guangdong. Actual price changes depend on enterprise confirmations, appeal adjudications and system data as of the batch cut‑off date, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100576933975691264

Guangdong Drug Exchange Center Publishes First Batch of Newly Listed Medical Consumables for September 2026 – Batch GDHCTYGW34‑20260901 Enters Unified Listing Catalogue, Enabling Hospital Contract Transactions

Listing Snapshot

Item	Detail
Authority	Guangdong Drug Exchange Center (Guangdong Province, China)
Action	Publication of newly listed (挂网) medical consumable products
Batch	September 2026, First Batch – GDHCTYGW34‑20260901
Publication Date	16 September 2026
Product Count	Not disclosed in the notice; full product information table attached to the official notice
Status	Products unified into the “Unified Medical Consumables Listing Catalogue” effective immediately
Policy Basis	Announcements on unifying the province‑wide newly added consumables listing process and on optimizing consumables listing management

Listing Details & Platform Access

Result Access: Applicant enterprises can log in to the Guangdong Drug and Medical Consumables Procurement Subsystem using a CA certificate and view outcomes via “Consumables Centralized Procurement Management – Consumables Listing Application – Published Results.”
Transaction Precondition: Medical institutions may initiate contract transactions only after the listed product’s delivery relationship meets requirements — the gating step between listing publication and actual hospital purchasing.
Action Required: Declaring enterprises are urged to complete delivery relationship maintenance in the procurement subsystem as soon as possible to avoid transaction delays; the operation guide is downloadable from the platform’s “Member Services – Procedural Guide” section.
Product Scope: Specific products, categories and quantities were not disclosed in the notice text; they are enumerated in the attached batch product information table.

Sector Background

Listing (挂网) Mechanism: In China’s provincial procurement architecture, “listing” registers a consumable product on the official exchange platform with declared pricing, enabling public hospitals to transact through the centralized system — a prerequisite for hospital market access in the province.
Guangdong’s Scale: As one of China’s largest provincial medical consumables markets, Guangdong’s exchange platform processes high‑volume listing batches on a rolling schedule, with the batch numbering (GDHCTYGW34‑20260901) reflecting a systematic, periodic publication cadence.
Process Unification: The referenced announcements standardized the province‑wide newly added listing process and optimized listing management — part of a broader national push toward consistent, transparent consumables procurement administration across provinces.

Market Impact & Outlook

Market Access Milestone: Enterprises with products in this batch gain immediate eligibility for hospital transactions across Guangdong once delivery relationships are validated — converting regulatory listing into commercial opportunity.
Compliance Urgency: The gap between listing publication and transactability hinges on delivery relationship maintenance; manufacturers slow to complete this step risk losing early sales windows to competitors already transacting.
Pricing Transparency: Listing places products in the unified catalogue with declared prices visible within the platform, reinforcing price benchmarking pressure across the provincial consumables market.
Forward Pipeline: Subsequent monthly batches will follow the same rolling cadence — suppliers not included in this batch should track upcoming September and October publications and ensure CA certificate credentials and delivery networks are pre‑positioned.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the listing, transaction readiness and commercial uptake of medical consumables published in Guangdong’s September 2026 first batch. Actual transaction volumes, delivery relationship approvals and market performance depend on platform processes, enterprise compliance and hospital procurement decisions, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=2100141153948012544